Chris Varma

BREAKING

Blueprint Medicines acquired by Sanofi for $9B+ Frontier Medicines doses first patient in PROSPER Phase 1/2 trial FMC-376: first-in-class dual ON/OFF KRAS G12C inhibitor Series C: $80M raised in one of biotech's hardest fundraising climates $315M+ raised to unlock the undruggable proteome 150,000+ hotspots mapped. 90% of the human proteome. One obsession. Blueprint Medicines acquired by Sanofi for $9B+ Frontier Medicines doses first patient in PROSPER Phase 1/2 trial FMC-376: first-in-class dual ON/OFF KRAS G12C inhibitor Series C: $80M raised in one of biotech's hardest fundraising climates $315M+ raised to unlock the undruggable proteome 150,000+ hotspots mapped. 90% of the human proteome. One obsession.

Who He Is

The proteome
is a frontier.
He named the company accordingly.

The drug you're hoping exists for the cancer no one can treat - the target your oncologist calls "undruggable" - there's a 90% chance it's exactly the kind of protein Chris Varma built Frontier Medicines to find. That number comes from a century of pharmaceutical history. Only about 10% of the human proteome has been accessible to small-molecule drugs. The rest has been off-limits - structurally cryptic, disordered, too dynamic for conventional chemistry.

Varma's answer wasn't to give up on the chemistry. It was to map the entire protein landscape first. Frontier's Druggability Atlas now covers more than 150,000 binding hotspots across more than 90% of the human proteome - built using a proprietary combination of chemoproteomics, covalent chemistry, and machine learning. Think of it as a new geological survey of a continent that pharma had been navigating with outdated maps.

The platform's first clinical test is FMC-376, a drug that does something its predecessors couldn't: it blocks KRAS G12C in both its active and inactive conformations simultaneously. A dual-acting inhibitor, more than 1,000-fold more potent at blocking key protein interactions than prior single-state drugs. KRAS is mutated in roughly 13% of all cancers - lung, pancreas, colorectal. The PROSPER Phase 1/2 trial is now enrolling patients.

"Over the last 100-plus years of pharmaceutical drug development, we've only been able to access about 10% of human protein targets. We haven't been able to access the other 90% where a lot of very important disease-causing proteins lie."

- Chris Varma, on why Frontier Medicines exists

None of this is his first rodeo. Varma co-founded Blueprint Medicines in 2010, took it public on Nasdaq in 2015, and in 2025 watched Sanofi write a check for over $9 billion to acquire it. He co-founded Warp Drive Bio, which Revolution Medicines acquired in 2018. Before those: investor roles at MPM Capital, Third Rock Ventures, and Flagship Pioneering - the same firms that built Moderna, Intellia, and dozens of other names you now recognize from press releases and pill bottles.

His career has a particular shape to it. Not the straight arc of the scientist who becomes a CEO. More like someone who deliberately learned every layer of the industry before doing something with all of it. FDA regulator. Pharma consultant. Biotech executive. Venture partner. Entrepreneur-in-residence. Then founder, again and again, each time with a harder problem and a sharper set of tools.

Quick Facts

Career Arc

Every role was preparation for the next one.

Early Career

U.S. Food and Drug Administration, Office of Combination Products - started where regulation meets science

Early 2000s

Millennium Pharmaceuticals, Personalized Medicine Group - consultant on early precision medicine initiatives

Mid 2000s

Novartis AG - senior roles spanning business development, corporate strategy, and sales & marketing

~2007-2010

Flagship Pioneering - Partner. Also served as President & CEO of Selventa, a Flagship portfolio company

2010

Co-founded Blueprint Medicines at Third Rock Ventures; raised $40M Series A. Also co-founded Warp Drive Bio at Third Rock

April 2015

Blueprint Medicines IPO on Nasdaq (BPMC) - a decade-long build from startup to public company

~2016-2018

Venture Partner at MPM Capital, focused on oncology investments

2018

Warp Drive Bio acquired by Revolution Medicines. Co-founded Frontier Medicines (March 2018)

September 2019

Frontier Medicines launches publicly with $67M Series A, led by Deerfield Management, Droia Ventures, and MPM Capital

July 2021

Frontier closes $88.5M Series B, co-led by Woodline Partners and RA Capital Management

2023

Frontier achieves AbbVie milestone payment from strategic partnership targeting undruggable transcription factors

February 2024

$80M oversubscribed Series C closed; first patient dosed in PROSPER Phase 1/2 trial with FMC-376. Galapagos NV joins as strategic investor

2025

Blueprint Medicines acquired by Sanofi for over $9 billion - a co-founded company reaching its full value 15 years after launch

The Platform

Three technologies. One mission: access the inaccessible.

The Frontier Platform combines chemoproteomics, covalent chemistry, and machine learning to find druggable pockets where none were thought to exist.

🔬

Chemoproteomics

Maps covalent binding hotspots across thousands of proteins in disease-relevant cell contexts. The Druggability Atlas covers more than 150,000 hotspots - a survey of the proteome that didn't exist before Frontier built it.

⚗️

Covalent Chemistry

Purpose-built covalent fragment libraries probe cryptic binding sites - pockets that only appear in the right protein conformation, in the right cellular context. The chemistry goes where conventional screening can't.

🤖

Machine Learning

ML models trained on proprietary proteome data accelerate target identification, selectivity optimization, and lead progression. Varma's MIT PhD work in ML in biomedical sciences laid the conceptual foundation for this approach - two decades before it became fashionable.

🎯

FMC-376: The Dual KRAS Bet

First-in-class direct dual inhibitor of both ON-state and OFF-state KRAS G12C. Over 1,000-fold more potent than prior single-state inhibitors at blocking key protein-protein interactions. Active in lung, pancreatic, colorectal, and brain metastasis models. Now in Phase 1/2.

Frontier Medicines Funding

$315.5M raised. Each round harder than the last.

Series A
Sept 2019

Deerfield · Droia · MPM

$67M

Series B
July 2021

Woodline · RA Capital · Deerfield

$88.5M

Series C
Feb 2024

Deerfield · Droia · Galapagos

$80M

Total Capital Raised

$315.5M

The Portfolio of Bets

He doesn't just build companies. He builds categories.

Active

Frontier Medicines

Co-Founder, Chairman & CEO (2018-present)

Clinical-stage precision therapeutics company using chemoproteomics and covalent chemistry to unlock the undruggable proteome. Lead compound FMC-376 targets KRAS G12C in Phase 1/2. Based in South San Francisco.

Raised: $315.5M | Stage: Phase 1/2 Clinical

Acquired $9B+

Blueprint Medicines

Co-Founder & President/CEO (2010-~2016); Nasdaq IPO 2015

Precision oncology company built on kinase inhibitor biology, pioneering treatments for systemic mastocytosis (Ayvakit) and rare cancers. IPO'd 2015. Acquired by Sanofi in 2025 for $9B+.

Exit: Sanofi, $9B+ | Year: 2025

Acquired 2018

Warp Drive Bio

Co-Founder (at Third Rock Ventures)

Targeted oncology company applying helical mimetics and novel chemistry to historically inaccessible targets. Partnered with Sanofi for $125M before being acquired by Revolution Medicines in 2018.

Exit: Revolution Medicines | Year: 2018

The Financing Crucible

He called it harder than the Great Recession. He closed it anyway.

The biotech funding market of 2023 was brutal. Tech was recovering, pulling early-stage capital away from drug developers. Frontier was pre-revenue, pre-clinical, working on a biology that most investors found difficult to underwrite. Varma has been at this long enough to have raised money through the dot-com crash and the 2008 financial crisis.

He said the Series C was harder than either of those moments. Then he closed it oversubscribed at $80 million.

"I've been either an investor or an entrepreneur and CEO for a long time - well over two decades - and this is definitely one of the hardest financings I've ever done. This was worse than the financings I did during the eye of the financial crisis, even dating back to the dot-com bubble bust."

- Chris Varma, on closing Frontier's Series C

The Unusual Wiring

Computer scientist. Regulator. Investor. Then founder. In that order.

Most biotech CEOs come up through one path: science, then business. Or MBA, then biotech. Varma ran the longer route. B.S. and M.S. in Computer Science at Stanford. Management at Stanford. Then a Harvard-MIT joint PhD with an EECS qualifier at MIT and genetics work at Harvard Medical School - with machine learning as his emphasis. Before any of this was fashionable in pharma.

Then the FDA. Then Millennium Pharmaceuticals. Then Novartis. Then venture capital at three different firms - Flagship, Third Rock, MPM - each with a different investment thesis, a different stage focus, a different way of building companies from scratch.

He arrived at Frontier Medicines not as someone who learned drug discovery on the job. As someone who had seen it built from every conceivable angle - regulatory, commercial, scientific, financial - and chose the hardest version of the problem on purpose.

Education

The degrees are the roadmap to the company.

Ph.D. - Biomedical Sciences

Harvard-MIT Program in Health Sciences & Technology (HST)

Qualified in EECS (Course 6) at MIT with emphasis in machine learning applied to biomedical sciences. Genetics concentration at Harvard Medical School.

M.S. - Management

Stanford University

Business and organizational strategy alongside deep technical training - the bridge between Varma's scientific depth and his eventual role as CEO and venture builder.

M.S. + B.S. - Computer Science

Stanford University

Foundation in computation, algorithms, and machine learning - skills he would later apply to proteome-scale drug discovery years before that became an industry trend.

Beyond the Company

Advisory & Board Roles

Council Member

Harvard Medical School Discovery Council

Board of Trustees

International Vaccine Institute

Venture Roles (prior)

MPM Capital · Third Rock Ventures · Flagship Pioneering

His Guiding Principle

"Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it is the only thing that ever has."

- Margaret Mead (Chris Varma's chosen epigraph, posted on his Frontier Medicines profile)

The same quote that MIT engineers, civil rights leaders, and UN commissioners reach for. In Varma's case, the small group in question is trying to rewrite the rules of what a drug can target.

Follow the Work

Sources & Social Links

🌎 Frontier Medicines 👤 Official Bio 🔗 LinkedIn 🔗 Frontier on X/Twitter 📰 Fierce Biotech Interview 📰 BioPharma Dive 📰 Series C Press Release